# Orsobio

> Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. Last analyzed September 14, 2026.

> OrsoBio is a biotechnology company focused on developing novel oral therapeutics for severe metabolic disorders, including severe hypertriglyceridemia (SHTG), metabolic dysfunction–associated steatotic liver disease (MASLD)/MASH, and obesity. The company is advancing drugs like TLC-2716 and TLC-6740 through clinical trials.

- Business Profile: https://optimly.ai/brand/orsobio
- Publisher: Optimly (https://optimly.ai)
- Dataset: Optimly AI Brand Index (https://optimly.ai/brand)
- Official website: https://fiercebiotech.com/
- Logo: https://logo.clearbit.com/fiercebiotech.com
- Slug: orsobio
- Brand Authority Index tier: Low Visibility
- Category: Pharmaceutical Companies
- Last Analyzed: September 14, 2026

## Buyer Intent Signals
Problems: Severe hypertriglyceridemia (SHTG) | Metabolic dysfunction–associated steatotic liver disease (MASLD) | Metabolic dysfunction-associated steatohepatitis (MASH) | Obesity | Elevated remnant cholesterol | Excessive lipid production
Solutions: Oral drug development for metabolic disorders | LXR inverse agonist therapy | Mitochondrial protonophore therapy | Reduction of fasting triglycerides | Improvement of hepatic fat | Weight management solutions | Therapeutic options for severe metabolic disorders
Comparisons: Clinical trial results | Phase 2a data analysis | Phase 2b study planning | Drug safety and tolerability assessment | Efficacy of metabolic disorder treatments | Biotech financing and partnerships | LXR inverse agonism validation